Feature | June 17, 2013

PET/MR Effective for Imaging Recurrent Prostate Cancer

Study reveals new hybrid molecular imaging system is as good as PET/CT gold standard for restaging patients with metastatic prostate cancer

 Prostate MRI showing tumor 2_From Philips MRI webinar for ITN

When prostate cancer makes a comeback, it becomes increasingly important to have exceptional imaging available to find all possible regions where cancer has spread to other parts of the body, or metastasized, in order to plan the best possible treatment. A relatively new imaging system that simultaneously combines positron emission tomography and magnetic resonance (PET/MR) demonstrates a higher capacity for mapping recurrent prostate cancer than the already high standard of integrated PET and computed tomography (PET/CT), say researchers presenting a study at the Society of Nuclear Medicine and Molecular Imaging’s 2013 Annual Meeting.

PET/MR provides superb soft tissue contrast with its MR component, compared to PET/CT, which focuses more on structure and density imaging with CT. This study ushers PET/MR into the ring of clinical practice by exhibiting clear benefits for prostate cancer patients with metastatic tumors.

In this comparative study recurrent prostate cancer is imaged both with PET/MR and PET/CT with the molecular imaging agent C-11 choline, which was approved for this use by the U.S. Food and Drug Administration (FDA) last year. Choline is a naturally occurring B vitamin complex that is avidly bound by prostate cells upon injection, even those that have traveled through the bloodstream and taken up residence to develop metastatic tumors elsewhere, which is especially likely in the lymph nodes and in bone. 

“The combination of PET, here with C-11 choline, and functional MRI provides complementary information that increases diagnostic certainty with higher detection rates, especially for more precise localization of recurrence. This could help to better tailor specific therapy, e.g., radiation of the pelvis versus antihormonal therapy, for patients with metastatic prostate cancer,” said Matthias Eiber, MD, lead scientist for the study from TU Muenchen in Munich, Germany.

Methodology included a study population of 31 patients who had both PET/CT and PET/MR performed for restaging of recurrent prostate cancer with single injection of the imaging agent C-11 choline. PET/CT scans occurred about five minutes after injection, and PET/MR scans occurred about 51 minutes after injection. Scans were interpreted separately and all detected lesions were categorized according to suspected metastases as definitely, probably or indeterminately metastatic. Researchers discovered that PET/MR found more areas of metastases—17 in 12 different patients—when compared to PET/CT, which found 12 areas of metastases in eight subjects. PET/MR also found more lymph node metastases, 42 versus 39 areas of interest with PET/CT. The same held true for bone metastases, which were detected in 17 areas for five patients with PET/MR and 14 areas for four patients with PET/CT. 

Simultaneous PET/MR is comparable to—if not more powerful than—PET/CT for recurrent prostate cancer. The only obvious challenge was a longer scan time than PET/CT, but it was found to be tolerable by patients undergoing PET/MR. PET/MR additionally offers considerably lower radiation exposure compared to PET/CT. As many of these patients often get a series of examinations in the course of their disease, despite their high average age, radiation protection could be another argument for the promotion of PET/MR. This molecular imaging technique can now be considered a conceivable alternative to PET/CT for restaging prostate metastases, especially when small local tumor recurrences are involved.

“In principle, whole-body integrated PET/MR is a technique that is officially commercially available; however, so far only a limited number of these scanners have been installed worldwide,” said Eiber. “Showing a concrete example of how combining PET and functional MR imaging benefits patients with metastatic prostate cancer could potentially motivate continued PET/MR research in this field.”

Scientific Paper 343: Matthias Eiber, Michael Souvatzoglou, Tobias Maurer, Sibylle Ziegler, Ernst Rummeny, Markus Schwaiger, Ambros Beer, Radiology, TU Muenchen, Munich, Germany; Nuclear Medicine, TU Muenchen, Munich, Germany; Urology, TU Muenchen, Munich, Germany, “Initial experience in restaging of patients with recurrent prostate cancer: Comparison of 11C-Choline-PET/MR and 11C-Choline-PET/CT,” SNMMI’s 60th Annual Meeting, June 8–12, 2013, Vancouver, British Columbia.

For more information: www.snmmi.org

Related Content

Videos | SPECT-CT | December 12, 2018
This is a walk around of the new Spectrum Dynamics Veriton SPECT-CT nuclear imaging system introduced at the 2018 ...
YITU Releases AI-Based Cancer Screening Solutions at RSNA 2018
News | Artificial Intelligence | December 06, 2018
Chinese artificial intelligence (AI) healthcare company YITU healthcare released two brand-new products, Intelligent...
Siemens Healthineers Showcases syngo Virtual Cockpit for More Flexible Workforce Management
News | Teleradiology | November 25, 2018
During the 104th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Nov. 25-30...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
News | Advanced Visualization | November 13, 2018
Canon Medical Systems USA and Applied Radiology will host a pair of expert-led forums in high-resolution imaging and...